Clinical Relevance and Role of Neuronal AT1 Receptors in ADAM17-Mediated ACE2 Shedding in Neurogenic Hypertension

Circulation Research

Volumn 121, Issue 1, 2017, Pages 43-55

  Xu, Jiaxi ^a,b   Sriramula, Srinivas ^a,b   Xia, Huijing ^a,b   Moreno Walton, Lisa ^a   Culicchia, Frank ^a   Domenig, Oliver ^d   Poglitsch, Marko ^d   Lazartigues, Eric ^a,b,c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d Attoquant Diagnostics GmbH   (Austria)

Author keywords

ACE2; central nervous system; hypertension; renin angiotensin system; TNF convertase enzyme

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; DEOXYCORTICOSTERONE ACETATE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; ADAM17 PROTEIN, MOUSE; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME ACTIVITY; HYPERTENSION; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; ANIMAL; CELL CULTURE; FEMALE; HUMAN; HYPOTHALAMUS; KNOCKOUT MOUSE; MALE; METABOLISM; NERVE CELL; NEWBORN; PHYSIOLOGY; TRANSGENIC MOUSE;

ADAM17 PROTEIN; ADULT; ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; CELLS, CULTURED; FEMALE; HUMANS; HYPERTENSION; HYPOTHALAMUS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEURONS; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, ANGIOTENSIN, TYPE 1;

EID: 85019871485     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.310509     Document Type: Article

References (50)

1. Doobay MF, Talman LS, Obr TD, Tian X, Davisson RL, Lazartigues E. Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. 2007;292:R373-R381. doi: 10.1152/ ajpregu.00292.2006.
2. Xia H, Lazartigues E. Angiotensin-converting enzyme 2: central regulator for cardiovascular function. Curr Hypertens Rep. 2010;12:170-175. doi: 10.1007/s11906-010-0105-7.
3. Xia H, Feng Y, Obr TD, Hickman PJ, Lazartigues E. Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice. Hypertension. 2009;53:210-216. doi: 10.1161/HYPERTENSIONAHA.108.123844.
4. Yamazato M, Yamazato Y, Sun C, Diez-Freire C, Raizada MK. Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension. 2007;49:926-931. doi: 10.1161/01.HYP.0000259942.38108.20.
5. Xia H, Sriramula S, Chhabra KH, Lazartigues E. Brain angiotensinconverting enzyme type 2 shedding contributes to the development of neurogenic hypertension. Circ Res. 2013;113:1087-1096. doi: 10.1161/ CIRCRESAHA.113.301811.
6. Deshotels MR, Xia H, Sriramula S, Lazartigues E, Filipeanu CM. Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension. 2014;64:1368-1375. doi: 10.1161/ HYPERTENSIONAHA.114.03743.
7. Xu J, Mukerjee S, Silva-Alves CR, Carvalho-Galvão A, Cruz JC, Balarini CM, Braga VA, Lazartigues E, França-Silva MS. A Disintegrin and Metalloprotease 17 in the Cardiovascular and Central Nervous Systems. Front Physiol. 2016;7:469. doi: 10.3389/fphys.2016.00469.
8. Shi P, Diez-Freire C, Jun JY, Qi Y, Katovich MJ, Li Q, Sriramula S, Francis J, Sumners C, Raizada MK. Brain microglial cytokines in neurogenic hypertension. Hypertension. 2010;56:297-303. doi: 10.1161/ HYPERTENSIONAHA.110.150409.
9. Lanz TV, Ding Z, Ho PP, Luo J, Agrawal AN, Srinagesh H, Axtell R, Zhang H, Platten M, Wyss-Coray T, Steinman L. Angiotensin II sustains brain inflammation in mice via TGF-beta. J Clin Invest. 2010;120:2782-2794. doi: 10.1172/JCI41709.
10. Biancardi VC, Stranahan AM, Krause EG, de Kloet AD, Stern JE. Cross talk between AT1 receptors and Toll-like receptor 4 in microglia contributes to angiotensin II-derived ROS production in the hypothalamic paraventricular nucleus. Am J Physiol Heart Circ Physiol. 2016;310:H404-H415. doi: 10.1152/ajpheart.00247.2015.
11. Basting T, Lazartigues E. DOCA-salt hypertension: an update. Curr Hypertens Rep. 2017;19:32. doi: 10.1007/s11906-017-0731-4.
12. Li W, Peng H, Mehaffey EP, Kimball CD, Grobe JL, van Gool JM, Sullivan MN, Earley S, Danser AH, Ichihara A, Feng Y. Neuronspecific (pro)renin receptor knockout prevents the development of saltsensitive hypertension. Hypertension. 2014;63:316-323. doi: 10.1161/ HYPERTENSIONAHA.113.02041.
13. Marvar PJ, Thabet SR, Guzik TJ, Lob HE, McCann LA, Weyand C, Gordon FJ, Harrison DG. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res. 2010;107:263-270. doi: 10.1161/ CIRCRESAHA.110.217299.
14. Wang X, Oka T, Chow FL, Cooper SB, Odenbach J, Lopaschuk GD, Kassiri Z, Fernandez-Patron C. Tumor necrosis factor-alpha-converting enzyme is a key regulator of agonist-induced cardiac hypertrophy and fibrosis. Hypertension. 2009;54:575-582. doi: 10.1161/ HYPERTENSIONAHA.108.127670.
15. Soond SM, Everson B, Riches DW, Murphy G. ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci. 2005;118:2371-2380. doi: 10.1242/ jcs.02357.
16. Sriramula S, Xia H, Xu P, Lazartigues E. Brain-targeted angiotensinconverting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation. Hypertension. 2015;65:577-586. doi: 10.1161/HYPERTENSIONAHA.114.04691.
17. Xu P, Derynck R. Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. Mol Cell. 2010;37:551-566. doi: 10.1016/j.molcel.2010.01.034.
18. de Queiroz TM, Xia H, Filipeanu CM, Braga VA, Lazartigues E. α-Lipoic acid reduces neurogenic hypertension by blunting oxidative stress-mediated increase in ADAM17. Am J Physiol Heart Circ Physiol. 2015;309:H926-H934. doi: 10.1152/ajpheart.00259.2015.
19. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011;32:380-387. doi: 10.1016/j.it.2011.05.005.
20. Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005;280:30113-30119. doi: 10.1074/jbc.M505111200.
21. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1-E9.
22. Karamyan VT, Speth RC. Enzymatic pathways of the brain renin-angiotensin system: unsolved problems and continuing challenges. Regul Pept. 2007;143:15-27. doi: 10.1016/j.regpep.2007.03.006.
23. Epelman S, Tang WH, Chen SY, Van Lente F, Francis GS, Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. J Am Coll Cardiol. 2008;52:750-754. doi: 10.1016/j. jacc.2008.02.088.
24. Úri K, Fagyas M, Mányiné Siket I, Kertész A, Csanádi Z, Sándorfi G, Clemens M, Fedor R, Papp Z, Édes I, Tóth A, Lizanecz E. New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure. PLoS One. 2014;9:e87845. doi: 10.1371/journal.pone.0087845.
25. Jia HP, Look DC, Tan P, Shi L, Hickey M, Gakhar L, Chappell MC, Wohlford-Lenane C, McCray PB Jr. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol. 2009;297:L84-L96. doi: 10.1152/ajplung.00071.2009.
26. Cherney DZ, Xiao F, Zimpelmann J, Har RL, Lai V, Scholey JW, Reich HN, Burns KD. Urinary ACE2 in healthy adults and patients with uncomplicated type 1 diabetes. Can J Physiol Pharmacol. 2014;92:703-706. doi: 10.1139/cjpp-2014-0065.
27. Shen XZ, Li Y, Li L, Shah KH, Bernstein KE, Lyden P, Shi P. Microglia participate in neurogenic regulation of hypertension. Hypertension. 2015;66:309-316. doi: 10.1161/HYPERTENSIONAHA.115.05333.
28. Stern JE, Son S, Biancardi VC, Zheng H, Sharma N, Patel KP. Astrocytes contribute to angiotensin II stimulation of hypothalamic neuronal activity and sympathetic outflow. Hypertension. 2016;68:1483-1493.
29. Villapol S, Saavedra JM. Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens. 2015;28:289-299. doi: 10.1093/ajh/hpu197.
30. Weskamp G, Mendelson K, Swendeman S, Le Gall S, Ma Y, Lyman S, Hinoki A, Eguchi S, Guaiquil V, Horiuchi K, Blobel CP. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ Res. 2010;106:932-940. doi: 10.1161/ CIRCRESAHA.109.207415.
31. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, Nakashima H, Eguchi K, Eguchi S. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol. 2006;26:e133-e137. doi: 10.1161/01.ATV.0000236203.90331.d0.
32. Palazuelos J, Crawford HC, Klingener M, Sun B, Karelis J, Raines EW, Aguirre A. TACE/ADAM17 is essential for oligodendrocyte development and CNS myelination. J Neurosci. 2014;34:11884-11896. doi: 10.1523/ JNEUROSCI.1220-14.2014.
33. Ishizaka N, Griendling KK, Lassègue B, Alexander RW. Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension. 1998;32:459-466.
34. Adebiyi A, Soni H, John TA, Yang F. Lipid rafts are required for signal transduction by angiotensin II receptor type 1 in neonatal glomerular mesangial cells. Exp Cell Res. 2014;324:92-104. doi: 10.1016/j.yexcr.2014.03.011.
35. Ushio-Fukai M, Alexander RW. Caveolin-dependent angiotensin II type 1 receptor signaling in vascular smooth muscle. Hypertension. 2006;48:797-803. doi: 10.1161/01.HYP.0000242907.70697.5d.
36. Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, Putko B, Kassiri Z, Turner AJ, Oudit GY. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol. 2014;66:167-176. doi: 10.1016/j.yjmcc.2013.11.017.
37. Melenhorst WB, Visser L, Timmer A, van den Heuvel MC, Stegeman CA, van Goor H. ADAM17 upregulation in human renal disease: a role in modulating TGF-alpha availability? Am J Physiol Renal Physiol. 2009;297:F781-F790. doi: 10.1152/ajprenal.90610.2008.
38. Soler MJ, Wysocki J, Batlle D. ACE2 alterations in kidney disease. Nephrol Dial Transplant. 2013;28:2687-2697. doi: 10.1093/ndt/gft320.
39. Elliott KJ, Bourne AM, Takayanagi T, Takaguri A, Kobayashi T, Eguchi K, Eguchi S. ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells. J Mol Cell Cardiol. 2013;62:1-7. doi: 10.1016/j. yjmcc.2013.05.005.
40. Li W, Sullivan MN, Zhang S, Worker CJ, Xiong Z, Speth RC, Feng Y. Intracerebroventricular infusion of the (Pro)renin receptor antagonist PRO20 attenuates deoxycorticosterone acetate-saltinduced hypertension. Hypertension. 2015;65:352-361. doi: 10.1161/ HYPERTENSIONAHA.114.04458.
41. Santisteban MM, Ahmari N, Carvajal JM, Zingler MB, Qi Y, Kim S, Joseph J, Garcia-Pereira F, Johnson RD, Shenoy V, Raizada MK, Zubcevic J. Involvement of bone marrow cells and neuroinflammation in hypertension. Circ Res. 2015;117:178-191. doi: 10.1161/ CIRCRESAHA.117.305853.
42. Porro C, Trotta T, Panaro MA. Microvesicles in the brain: Biomarker, messenger or mediator? J Neuroimmunol. 2015;288:70-78. doi: 10.1016/j. jneuroim.2015.09.006.
43. Saxena A, Bachelor M, Park YH, Carreno FR, Nedungadi TP, Cunningham JT. Angiotensin II induces membrane trafficking of natively expressed transient receptor potential vanilloid type 4 channels in hypothalamic 4B cells. Am J Physiol Regul Integr Comp Physiol. 2014;307:R945-R955. doi: 10.1152/ajpregu.00224.2014.
44. Li Y, Trush MA. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem Biophys Res Commun. 1998;253:295-299. doi: 10.1006/ bbrc.1998.9729.
45. Riganti C, Gazzano E, Polimeni M, Costamagna C, Bosia A, Ghigo D. Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem. 2004;279:47726-47731. doi: 10.1074/jbc. M406314200.
46. Rosenbaugh EG, Savalia KK, Manickam DS, Zimmerman MC. Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases. Am J Physiol Regul Integr Comp Physiol. 2013;304:R917-R928. doi: 10.1152/ajpregu.00395.2012.
47. Kalyanaraman B, Darley-Usmar V, Davies KJ, Dennery PA, Forman HJ, Grisham MB, Mann GE, Moore K, Roberts LJ 2nd, Ischiropoulos H. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic Biol Med. 2012;52:1-6. doi: 10.1016/j.freeradbiomed.2011.09.030.
48. Nazarewicz RR, Bikineyeva A, Dikalov SI. Rapid and specific measurements of superoxide using fluorescence spectroscopy. J Biomol Screen. 2013;18:498-503. doi: 10.1177/1087057112468765.
49. Kohno M. Applications of electron spin resonance spectrometry for reactive oxygen species and reactive nitrogen species research. J Clin Biochem Nutr. 2010;47:1-11. doi: 10.3164/jcbn.10-13R.
50. Salem ES, Grobe N, Elased KM. Insulin treatment attenuates renal ADAM17 and ACE2 shedding in diabetic Akita mice. Am J Physiol Renal Physiol. 2014;306:F629-F639. doi: 10.1152/ajprenal.00516.2013.